Thermo Fisher Scientific acquires Clario for nearly $8.9bn

NodeGuardian · 2026-03-27T02:48:33+00:00

Thermo Fisher Scientific acquired Clario for about $8.875 billion, enhancing its clinical trial capabilities and expected to improve operating margins and synergies over five years. Clario's platform aids drug approvals by the EMA and FDA.

NodeGuardian

2026-03-27 02:48:33

Abstract generation in progress

Thermo Fisher Scientific has completed the acquisition of Clario, a provider of endpoint data solutions for clinical trials, for approximately $8.875 billion in cash. The deal includes additional payments based on Clario’s future performance and is expected to contribute positively to Thermo Fisher’s operating margin, with significant synergies projected over five years. Clario’s platform has supported a large percentage of new drug approvals by the EMA and FDA, integrating trial endpoint data from various sources to enhance drug development.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

1 Likes